PBF 1129

Drug Profile

PBF 1129

Alternative Names: PBF-1129

Latest Information Update: 13 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Palobiofarma
  • Developer Ohio State University; Palobiofarma
  • Class Antifibrotics; Antineoplastics
  • Mechanism of Action Adenosine A2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Idiopathic pulmonary fibrosis; Non-small cell lung cancer

Most Recent Events

  • 12 Apr 2018 US FDA grants approval to initiate phase I trial in Lung cancer
  • 12 Mar 2018 Phase-I clinical trials in Idiopathic pulmonary fibrosis in Spain (PO) (Palobiofarma pipeline, March 2018)
  • 12 Mar 2018 Phase-I clinical trials in Non-small cell lung cancer (Late-stage disease, Metastatic disease) in USA (PO) (Palobiofarma pipeline, March 2018) (NCT03274479)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top